Search results
Showing 1 to 6 of 6 results for sotorasib
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
In development Reference number: GID-TA11484 Expected publication date: TBC
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Awaiting development Reference number: GID-TA11967 Expected publication date: TBC
Discontinued Reference number: GID-TA11289
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.